HERZLIYA, Israel and Calgary, AB , Oct. 16, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF ) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, is pleased to announce that it will be presenting at the 2024 ThinkEquity Investor Conference taking place on October 30 at the Mandarin Oriental Hotel in New York, NY . The Company will be discussing its recently achieved significant regulatory milestones, in particular, securing a U.
S. Food and Drug Administration (FDA) approval for a 505(2)(b) abbreviated pathway for its human health applications. This included a sponsor fee waiver and an Investigational New Animal Drug number (INAD) for its animal health applications from the FDA Center for Veterinary Medicine.
Iris Bincovich, CEO of Innocan Pharma, will be presenting at the investor conference on Wednesday, October 30th at 2:00pm ET (also viewable online at the conference portal). The Company's executive team will be available for one-on-one meetings at the event. Interested investors can register to meet with Innocan leadership at: https://www.
meetmax.com/sched/event_106721/conference_register.html The conference will feature over 75 companies in diverse technology, biotechnology and energy fields, presenting in half-hour increments, and will offer one-on-one meetings with investors and analysts.
With over 600 leading industry executives, institutional investors, and family offices in attendan.
